|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||52.46 - 52.50|
|52 Week Range||14.66 - 52.53|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct. 28, 2020 - Nov. 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.50|
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the successful completion of its sale to Johnson & Johnson for $52.50 per share, totaling approximately $6.5 billion. The all-cash tender offer by Vigor Sub, Inc. (“Vigor”), a wholly owned subsidiary of Johnson & Johnson, for all outstanding shares of Momenta common stock for $52.50 per share expired at 12:00 a.m. (midnight), New York City time, at the end of the day on September 30, 2020.
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: * Akcea Therapeutics, Inc.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the other hand, if you...